Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Greenbaum

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 18, 2015
Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cellsAntoine Tanne, Luciana R Muniz, Anna Puzio-Kuter, et al.
Nature|November 14, 2017
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyMarta Łuksza, Nadeem Riaz, Vladimir Makarov, et al.
Nature Communications|July 20, 2023
Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVectorNicholas Ceglia, Zachary Sethna, Samuel S Freeman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose CombinationJames W Smithy, Victoria Ciallella, Claire Thant, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose CombinationJames W Smithy, Victoria Ciallella, Claire Thant, et al.
Nature Immunology|February 5, 2025
Terminal differentiation and persistence of effector regulatory T cells essential for preventing intestinal inflammationStanislav Dikiy, Aazam P Ghelani, Andrew G Levine, et al.
Cancer Research|June 22, 2026
Immune checkpoint blockade augments lymphodepleting chemotherapy-induced antitumor immunity by expanding effector CD8+ T cell clonesMariam Mathew George, Linda Hamadene, Yacine Marouf, et al.
Nature Communications|March 25, 2025
Author Correction: Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiencyAlexander Solovyov, Julie M Behr, David Hoyos, et al.
Nature Communications|February 28, 2025
Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiencyAlexander Solovyov, Julie M Behr, David Hoyos, et al.
Ebiomedicine|December 10, 2025
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndromeEmilie Montellier, Olivier Manches, Jonathan Gaucher, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Proceedings of the National Academy of Sciences of the United States of America|November 18, 2015
Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cellsAntoine Tanne, Luciana R Muniz, Anna Puzio-Kuter, et al.
Nature|November 14, 2017
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyMarta Łuksza, Nadeem Riaz, Vladimir Makarov, et al.
Nature Communications|July 20, 2023
Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVectorNicholas Ceglia, Zachary Sethna, Samuel S Freeman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose CombinationJames W Smithy, Victoria Ciallella, Claire Thant, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose CombinationJames W Smithy, Victoria Ciallella, Claire Thant, et al.
Nature Immunology|February 5, 2025
Terminal differentiation and persistence of effector regulatory T cells essential for preventing intestinal inflammationStanislav Dikiy, Aazam P Ghelani, Andrew G Levine, et al.
Cancer Research|June 22, 2026
Immune checkpoint blockade augments lymphodepleting chemotherapy-induced antitumor immunity by expanding effector CD8+ T cell clonesMariam Mathew George, Linda Hamadene, Yacine Marouf, et al.
Nature Communications|March 25, 2025
Author Correction: Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiencyAlexander Solovyov, Julie M Behr, David Hoyos, et al.
Nature Communications|February 28, 2025
Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiencyAlexander Solovyov, Julie M Behr, David Hoyos, et al.
Ebiomedicine|December 10, 2025
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndromeEmilie Montellier, Olivier Manches, Jonathan Gaucher, et al.
Pageof 12